CodeBreak 300
04 May 2022
Trial Summary
A Phase 3, multicentre, randomisated, open-label, active-controlled Study of Sotorasib and Panitumumab (Vectibix) vs investigator’s choice (Trifluridine and Tipiracil or Regorafenib) in previously treated metastatic CRC patients with the KRAS G12C mutation
Acronym:
CodeBreak 300
ACTRN/NCT /ethics:
NCT05198934
Scientific title:
Sotorasib and Panitumumab Versus Investigator’s Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation (CodeBreak 300)
Sponsor / Cooperative group:
Amgen
Trial & Patient Characteristics
| Cancer Type | Bowel & colon |
|---|---|
| Trial Type | Treatment |
| Phase | Phase III |
| Age Range | 18 years to 100 years |
| Sex | All |
| Tumour Stream | - |
| Cancer Stage | Metastatic or Widespread |
| Anticipated Start Date | 2022-04-29 |
| Anticipated End Date | 2024-01-01 |
Participating Hospitals
| Hospital | The Queen Elizabeth Hospital |
|---|---|
| Clinical Trial Coordinator | Pamela Cooper |
| pamela.cooper@sa.gov.au | |
| Phone | 08 8222 6140 |
| Principal Investigator | Dr Timothy Price |
| Recruitment Status | Recruiting |